{"title":"Non-neovascular subretinal fluid secondary to choroidal osteoma controlled with intravitreal aflibercept – A case report","authors":"J. Brody, I. Avisar, Ehud Reich","doi":"10.15713/ins.clever.36","DOIUrl":null,"url":null,"abstract":"The aim of the study was to describe a case of subretinal fluid without neovascularization due to choroidal osteoma that was treated successfully with intravitreal aflibercept. Choroidal osteoma is an ossifying tumor that can cause visual impairment through several pathological mechanisms, including fluid accumulation under the retina, with or without choroidal neovascularization (CNV). We described a young adult man who presented with unilateral visual impairment due to choroidal osteoma without CNV, resistant to bevacizumab intravitreal injections, which showed a marked response to aflibercept. Our experience provides support for the use of aflibercept in the treatment of non-neovascular choroidal osteoma; this is the first report describing this encouraging result. Nevertheless, the current observation merits further research.","PeriodicalId":130091,"journal":{"name":"Clinical and Experimental Vision and Eye Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vision and Eye Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15713/ins.clever.36","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the study was to describe a case of subretinal fluid without neovascularization due to choroidal osteoma that was treated successfully with intravitreal aflibercept. Choroidal osteoma is an ossifying tumor that can cause visual impairment through several pathological mechanisms, including fluid accumulation under the retina, with or without choroidal neovascularization (CNV). We described a young adult man who presented with unilateral visual impairment due to choroidal osteoma without CNV, resistant to bevacizumab intravitreal injections, which showed a marked response to aflibercept. Our experience provides support for the use of aflibercept in the treatment of non-neovascular choroidal osteoma; this is the first report describing this encouraging result. Nevertheless, the current observation merits further research.